The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

For instance, studies have shown that approximately 25% of adults with diabetes reported rationing insulin in the previous ...

Global Generic Pharmaceuticals Market Poised for Robust Growth: Projected to Reach $916.2 Billion by 2033 with Strong Gains in Asia-Pacific and Emerging MarketsDublin, May 09, 2025 (GLOBE NEWSWIRE) -- ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore.

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...